RenovoRx, Inc.

RNXT

RenovoRx, Inc.

RNXT

Insider Sentiment (TTM):

Last Purchase:2026-05-19Last Sale:-Shares Purchased (TTM):220,220Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:8,520,830Shares Outstanding:38,032,421Institutional Ownership Pct.:22.40%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	9	12	7	10	12	15	7	10	12	4	1	3
Prepaid Expense And Other Assets Current	-	-	-	-	-	-	-	0	0	0	0	0
Deferred Offering Costs	-	-	-	-	-	-	-	-	-	0	0	0
Accounts Receivable Net Current	0	0	0	0	0	0	0	-	-	-	-	-
Prepaid Expense Current	0	1	0	0	0	0	0	-	-	-	0	-
Inventory Net	0	0	0	0	-	-	0	-	-	-	-	-
Other Assets Current	0	0	0	0	0	0	0	-	-	-	0	-
Assets Current	11	14	8	11	13	16	8	-	-	-	1	-
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	-	-	-	-	-
Property Plant And Equipment Net	0	0	0	0	0	0	0	-	-	-	-	-
Assets	11	14	8	11	14	16	8	10	12	5	1	4
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	1	1	1	1	1	1	0	0	1	0
Accrued Liabilities Current	1	1	1	1	1	1	1	1	1	1	1	1
Liabilities Current	2	2	2	2	2	2	2	2	1	1	1	2
Shares Subject To Mandatory Redemption Settlement …	0	1	1	1	1	1	2	1	1	2	3	2
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	-	-	-	-	-
Liabilities	2	3	3	3	3	3	4	3	3	3	4	4
Stockholders Equity
Preferred Stock Value	-	-	0	-	-	-	0	-	-	-	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	77	76	67	67	66	66	55	54	54	44	38	38
Retained Earnings Accumulated Deficit	-68	-65	-61	-58	-56	-53	-50	-47	-45	-42	-41	-38
Stockholders Equity	9	11	5	8	11	13	4	7	9	2	-3	0
Liabilities And Stockholders Equity	11	14	8	11	14	16	8	10	12	5	1	4
Preferred Stock Par Or Stated Value Per Share	-	-	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Authorized	-	-	15	15	15	15	15	15	15	15	15	-
Preferred Stock Shares Issued	-	-	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Outstanding	-	-	0	0	0	0	0	0	0	0	0	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	45	45	37	37	37	37	24	24	24	17	11	11
Shares Outstanding	45	45	37	37	37	37	24	24	24	17	11	11

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	1.99%	7.60%	10.06%	-	-	-	-	-	-	-	-	-
2025	25.23%	22.52%	9.01%	0.00%	6.45%	-10.48%	-3.39%	-14.27%	6.78%	-19.91%	-17.57%	-14.02%
2024	-20.00%	-22.07%	-11.10%	-12.07%	-12.07%	-12.07%	28.44%	26.61%	24.77%	3.13%	23.96%	43.75%
2023	-	-	-	-12.28%	-30.99%	-32.75%	-40.95%	64.76%	61.90%	-5.83%	-4.55%	-16.67%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.74	7.15	4.02	5.83	8.61	9.07	4.10	-	-	-	1.25	-
Quick Ratio	5.37	6.69	3.76	5.50	8.33	8.79	3.93	-	-	-	1.10	-
Working Capital	8.93M	11.80M	5.93M	9.10M	11.84M	14.01M	5.92M	-	-	-	291.00K	-
Leverage & Debt
Debt to Equity	0.28	0.24	0.49	0.39	0.28	0.22	0.81	0.42	0.29	1.71	-1.49	585.50
Interest Coverage TTM	-41.92	-35.16	-29.30	-26.59	-25.11	-25.62	-28.57	-32.63	-44.85	-75.26	-105.52	-106.21
Debt Ratio	0.22	0.19	0.33	0.28	0.22	0.18	0.45	-	-	-	3.05	-
Efficiency & Turnover
Asset Turnover TTM	0.16	0.10	0.14	0.08	0.05	0.01	0.00	-	-	-	0.00	-
Days Sales Outstanding TTM	77.86	63.98	29.58	69.70	214.05	448.38	-	-	-	-	-	-
Receivables Turnover TTM	4.69	5.70	12.34	5.24	1.71	0.81	0.00	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-0.02	-0.03	0.00	-0.30	-0.29	-0.32	-0.40	-0.37	-0.34	-0.54	-0.99	-0.86
Free Cash Flow Per Share TTM	-0.25	-0.30	-0.31	-0.19	-0.19	-0.33	-0.41	-0.35	-0.39	-0.65	-1.00	-0.92
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	84.41%	78.71%	70.88%	-	-	-	-	-	-	-	-	-
Operating Profit Margin TTM	-685.22%	-864.27%	-1,113.98%	-1,312.99%	-1,817.12%	-5,890.36%	-	-	-	-	-	-
Net Profit Margin TTM	-56.53%	-73.94%	0.00%	-1,254.80%	-1,722.78%	-5,156.35%	-	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	219.22%	655.84%	-	-	-	-	-	-	-	-	-	-
Net Income Growth (1Y)	-89.53%	-89.16%	-100.00%	21.19%	31.44%	26.17%	-13.86%	0.02%	-17.85%	-20.63%	3.47%	-26.98%
EPS Growth (1Y)	-91.90%	-91.05%	-100.00%	-17.52%	-13.58%	-39.93%	-60.20%	-57.12%	-63.60%	-51.73%	-8.99%	-38.08%
Valuation Metrics
P/E TTM	-41.50	-34.89	-	-4.19	-4.51	-3.06	-3.26	-2.89	-3.35	-2.49	-2.30	-1.55
P/B TTM	5.16	3.41	5.47	5.76	4.52	2.36	6.42	3.74	2.93	11.34	-7.86	2,370.30
P/S TTM	23.46	25.80	26.43	52.59	77.70	157.78	-	-	-	-	-	-
Market Cap	46.35M	38.41M	29.68M	46.54M	48.10M	31.08M	28.73M	26.44M	27.18M	20.03M	23.57M	14.22M
Enterprise Value	36.87M	26.05M	22.66M	36.50M	35.78M	16.50M	21.58M	16.87M	15.43M	15.64M	22.39M	11.00M
Calculated Values
Free Cash Flow TTM	-11.61M	-11.31M	-10.98M	-7.01M	-6.93M	-10.30M	-9.13M	-8.75M	-9.28M	-9.76M	-10.26M	-9.89M
Net Debt	-9.48M	-12.36M	-7.02M	-10.04M	-12.31M	-14.58M	-7.15M	-9.56M	-11.74M	-4.39M	-1.17M	-3.23M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-19Purchase

Owner: Voll, Mark

Title: Chief Financial Officer

Shares: 25,000

Price/Share: $0.79

Value: $19,750.00

Shares Owned: 142,380

Relationship: Officer

Ownership: Direct

2026-03-20Purchase

Owner: Voll, Mark

Title: Chief Financial Officer

Shares: 97,200

Price/Share: -

Value: -

Shares Owned: 97,200

Relationship: Officer

Ownership: Indirect

2026-03-20Purchase

Owner: Bagai, Shaun

Title: Chief Executive Officer

Shares: 24,300

Price/Share: -

Value: -

Shares Owned: 313,357

Relationship: Director,Officer

Ownership: Indirect

2026-03-20Purchase

Owner: Marton, Laurence

Title: -

Shares: 9,720

Price/Share: -

Value: -

Shares Owned: 9,720

Relationship: Director

Ownership: Indirect

2026-01-21Purchase

Owner: Agah, Ramtin

Title: Chief Medical Officer

Shares: 10,000

Price/Share: $1.00

Value: $10,000.00

Shares Owned: 798,460

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-19	Voll, Mark	Officer	Chief Financial Officer	Direct	Purchase	25,000	0.79	$19,750.00	142,380	4
2026-03-20	Voll, Mark	Officer	Chief Financial Officer	Indirect	Purchase	97,200	-	-	97,200	4
2026-03-20	Bagai, Shaun	Director,Officer	Chief Executive Officer	Indirect	Purchase	24,300	-	-	313,357	4
2026-03-20	Marton, Laurence	Director	-	Indirect	Purchase	9,720	-	-	9,720	4
2026-01-21	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	10,000	1.00	$10,000.00	798,460	4
2025-12-31	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	9,795	0.86	$8,423.70	788,460	4
2025-12-30	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	205	0.83	$170.15	778,665	4
2025-12-18	Bagai, Shaun	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	0.90	$4,500.00	340,040	4
2025-12-17	Bagai, Shaun	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	0.85	$4,250.00	335,040	4
2025-12-16	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	12,000	0.85	$10,200.00	778,460	4
2025-12-05	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	10,000	0.96	$9,600.00	766,460	4
2025-11-24	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	12,000	0.80	$9,600.00	756,460	4
2025-08-25	Bagai, Shaun	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	0.91	$4,550.00	330,040	4
2025-06-05	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	21,000	1.40	$29,400.00	734,460	4
2025-04-15	Bagai, Shaun	Director,Officer	Chief Executive Officer	Direct	Purchase	7,500	0.91	$6,825.00	320,040	4
2025-04-15	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	15,000	0.90	$13,500.00	1,113,460	4
2025-04-11	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	20,000	0.80	$16,000.00	1,098,460	4
2025-04-10	Kocak, Ron	Officer	VP Controller and PAO	Direct	Purchase	6,500	0.79	$5,135.00	12,595	4
2025-04-09	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	30,000	0.81	$24,300.00	1,078,460	4
2025-04-09	Bagai, Shaun	Director,Officer	Chief Executive Officer	Direct	Purchase	10,000	0.83	$8,300.00	312,540	4
2025-04-08	Marton, Laurence	Director	-	Direct	Purchase	12,050	0.85	$10,242.50	45,684	4
2025-04-08	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	26,000	0.84	$21,840.00	1,048,460	4
2025-04-07	Bagai, Shaun	Director,Officer	Chief Executive Officer	Direct	Purchase	10,000	0.83	$8,300.00	302,540	4
2024-01-26	Agah, Ramtin	Director,Officer	Chief Medical Officer	Direct	Purchase	40,983	-	-	47,460	4
2024-01-26	Spiegel, Robert J.	Director	-	Direct	Purchase	40,983	-	-	40,983	4
2024-01-26	Macfarlane, K. Angela	Director	-	Direct	Purchase	40,983	-	-	40,983	4
2024-01-26	Marton, Laurence	Director	-	Direct	Purchase	8,196	-	-	33,634	4
2024-01-26	Bagai, Shaun	Director,Officer	Chief Executive Officer	Direct	Purchase	40,983	-	-	292,540	4
2023-10-03	Nelms, Angela	Officer	Chief Operating Officer	Direct	Purchase	1,100	1.05	$1,155.00	1,100	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

22.40%

Inst. Shares: 8,520,830

Shares Outstanding: 38,032,421

2025-12-31

18.36%

Inst. Shares: 6,486,036

Shares Outstanding: 35,333,127

2025-09-30

19.34%

Inst. Shares: 7,088,085

Shares Outstanding: 36,646,278

2025-06-30

23.99%

Inst. Shares: 8,772,985

Shares Outstanding: 36,576,567

2025-03-31

32.09%

Inst. Shares: 10,076,151

Shares Outstanding: 31,395,888

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	8,520,830	38,032,421	22.40%
2025-12-31	6,486,036	35,333,127	18.36%
2025-09-30	7,088,085	36,646,278	19.34%
2025-06-30	8,772,985	36,576,567	23.99%
2025-03-31	10,076,151	31,395,888	32.09%
2024-12-31	1,013,351	22,271,163	4.55%
2024-09-30	1,890,069	24,940,746	7.58%
2024-06-30	883,285	24,049,113	3.67%
2024-03-31	329,531	14,947,500	2.20%
2023-12-31	317,051	10,290,667	3.08%
2023-09-30	363,630	10,693,080	3.40%
2023-06-30	244,336	10,655,155	2.29%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

RenovoRx, Inc. (RNXT) — SEC Financial Statements & Analysis

RenovoRx, Inc. (RNXT) is a pharmaceutical preparations company, incorporated in DE. RenovoRx, Inc. trades on Nasdaq as: RNXT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), RenovoRx, Inc. reported a 219.22% year-over-year revenue growth, a Gross Profit Margin of 84.41% (TTM), a Debt-to-Equity ratio of 0.28x, a Price-to-Sales (P/S) ratio of 23.46x (TTM), a Price-to-Book (P/B) ratio of 5.16x (TTM), at a market cap of $46.35M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 219.22%
Gross Profit Margin TTM: 84.41%
Debt To Equity: 0.28x
P/S TTM: 23.46x
P/B TTM: 5.16x
Market Cap: $46.35M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is RenovoRx, Inc. in?

RenovoRx, Inc. (RNXT) operates in the Pharmaceutical Preparations industry.

What is RNXT's market cap?

RenovoRx, Inc. (RNXT) has a market capitalization of $46.35M as of 2026-06-30.

What exchange does RNXT trade on?

RenovoRx, Inc. (RNXT) trades on the Nasdaq.

Where is RenovoRx, Inc. incorporated?

RenovoRx, Inc. is incorporated in DE.

RenovoRx, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

RenovoRx, Inc. (RNXT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

RenovoRx, Inc. (RNXT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.